NCT00457509已完成1 期
Safety and Immunogenicity of H5N1 Adjuvanted, Inactivated, Split-Virion Pandemic Influenza Vaccine in Healthy Adults
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 251
- 试验地点
- 3
- 主要终点
- To provide information concerning the safety of A/H5N1 Inactivated split influenza virus vaccine
研究概览
简要总结
The purpose of this study is to test different adjuvanted vaccine formulations as a two-dose schedule in immunologically naïve adults against one vaccine formulation without adjuvant in terms of tolerance and immunogenicity
Primary Objective:
To describe the safety profile and immunogenicity following each injection.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 40 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
To provide information concerning the safety of A/H5N1 Inactivated split influenza virus vaccine
时间窗: Entire study period
次要结局
未报告次要终点
研究者
研究点 (3)
Loading locations...
相似试验
Unknown
4 期
Safety and Immune Response to Adjuvanted A(H1N1)v Influenza Vaccine in HIV-1 Infected and Immunosuppressed Adult PatientsHIV-1 InfectionImmunosuppressionCancerNCT01017172Goethe University500
已完成
1 期
Safety and Immunogenicity Of A Recombinant H5N1 Vaccine In AdultsHealthyNCT01250795Fraunhofer, Center for Molecular Biotechnology100
已完成
2 期
A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Adults and the ElderlySwine-origin A/H1N1 InfluenzaInfluenzaNCT00953524Sanofi Pasteur, a Sanofi Company849
已完成
2 期
A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Children Aged 6 Months to 9 YearsSwine-origin A/H1N1 InfluenzaInfluenzaNCT00952419Sanofi Pasteur, a Sanofi Company474
已完成
2 期
A Study of Different Formulations of an Adjuvanted A/H1N1 Pandemic Vaccine in Healthy Adults and the ElderlySwine-origin A/H1N1 InfluenzaInfluenzaNCT00952276Sanofi548